ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement

Table 1 Characteristics of study participants at baseline by randomised treatment

	Placebo	0.45 g/day	0.9 g/day	1.8 g/day	P*
	n = 70	n = 80	n = 80	n = 80	P*
Gender
Male (%) n	31, 44	30, 38	30, 38	29, 36
Female (%) n	39, 56	50, 62	50, 62	51, 64
Age, years	55.37 ± 6.85	55.13 ± 6.84	55.15 ± 6.60	55.02 ± 6.71	0.995
BMI, kg/m²	26.13 ± 3.72	25.14 ± 3.88	26.16 ± 4.01	25.15 ± 3.50	0.172
Waist circumference, cm	89.50 ± 11.74	87.33 ± 11.80	89.42 ± 11.87	88.03 ± 11.00	0.602
Plasma fatty acid, % total
EPA	1.17 ± 0.59	1.10 ± 0.61	1.11 ± 0.56	1.10 ± 0.57	0.901
DPA	0.65 ± 0.10	0.64 ± 0.12	0.64 ± 0.13	0.65 ± 0.13	0.897
DHA	2.37 ± 0.68	2.44 ± 0.77	2.36 ± 0.67	2.47 ± 0.68	0.961

Data are presented for subjects who completed the study and for whom DNA was available (n = 310). Measurements taken at baseline after 4-week run-in on normal diet with olive oil placebo supplement are shown for each randomised treatment group: placebo and EPA and DHA (1.51:1) at the daily doses shown. Values are n (%) for male/female or mean ± SD for all other variables
BMI body mass index; EPA eicosapentaenoic acid; DPA docosapentaenoic acid; DHA docosahexaenoic acid
* Significance of differences between treatment groups assessed by one-way ANOVA. P-value for difference in age, adjusted for BMI, gender and ethnicity; for differences in BMI and waist circumference, adjusted for age, gender and ethnicity; for differences in plasma fatty acid proportions, adjusted for BMI, age, gender and ethnicity

ISSN: 1865-3499